Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triumeq in Amyotrophic Lateral Sclerosis
NCT05193994Phase 3Terminated
- Sponsor
- Macquarie University
- Start
- Feb 2022
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of abacavir in amyotrophic lateral sclerosis (ALS), sponsored by Macquarie University. Started Feb 2022; status: terminated.
02
Drugs
abacavir
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05193994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193994.